Meatly Raises $13M Series A to Build Europe's Largest Lab-Grown Meat Facility

Why It Matters

The investment validates the commercial viability of cultivated meat at scale and accelerates sustainable protein options for the pet‑food market, signaling broader industry momentum in Europe.

Key Takeaways

• Meatly secured $13.3 million Series A to fund 20,000‑litre pilot plant.
• Total funding now $22.3 million, combining seed and Series A rounds.
• Cost of protein‑free medium dropped to $0.28 per litre.
• Bioreactor expenses cut roughly ten‑fold, boosting scalability.
• First European cultivated‑meat firm, targeting pet food market by 2027.

Pulse Analysis

Cultivated meat, once confined to laboratory dishes, is rapidly moving toward industrial production as investors pour capital into scaling technologies. Meatly’s $13.3 million Series A injection underscores a broader shift: venture firms see cultivated protein not just as a niche novelty but as a mainstream solution to animal‑agriculture’s environmental footprint. By securing funding from specialized biotech investors, Meatly joins a growing cohort of startups that are leveraging bioreactor design, media cost reductions, and regulatory approvals to bridge the gap between proof‑of‑concept and market‑ready supply chains.

The financial backing also highlights Meatly’s strategic focus on cost engineering. Cutting the chemically defined, protein‑free medium to $0.28 per litre and slashing bioreactor costs by an order of magnitude directly tackles the two biggest price drivers in cell‑based meat production. These advances make it feasible to price cultivated protein competitively, especially in the pet‑food segment where consumers are willing to pay a premium for sustainable, ethically sourced ingredients. The 20,000‑litre pilot plant will serve as a testbed for these efficiencies, allowing the company to validate scale‑up metrics and refine its proprietary technology before a broader rollout.

Beyond the economics, Meatly’s move carries regulatory and market implications for Europe. Having secured UK approval in 2024 and completed a retail trial in 2025, the company is poised to leverage its first‑mover advantage as European regulators develop clearer pathways for cell‑based foods. The focus on pet nutrition provides a lower‑risk entry point, sidestepping some of the consumer acceptance hurdles present in the human food market. If successful, Meatly could set a template for other cultivated‑meat firms, accelerating the transition to a more sustainable protein ecosystem across the continent.

Deal Summary

Meatly, the UK pet-food producer of cultivated meat, announced a $13 million Series A round led by Oyster Bay Venture Capital, Clean Growth Fund and JamJar Investments. The funding will finance a 20,000-litre pilot bioreactor facility in London, the largest of its kind in Europe, and brings total capital raised to $22 million. The plant aims to commercialise cultivated meat for the pet-food market by 2027.